For stage IV NSCLC patients with sensitive EGFR mutations, first-line treatment options with a level I recommendation include EGFR tyrosine kinase inhibitors (TKIs), including first-, second-, and third-generation TKIs. Here, EGFR is linked to non-small cell lung carcinoma.